Literature DB >> 31895699

High residual C-peptide likely contributes to glycemic control in type 1 diabetes.

Michael R Rickels1, Carmella Evans-Molina2, Henry T Bahnson3, Alyssa Ylescupidez3, Kristen J Nadeau4, Wei Hao3, Mark A Clements5, Jennifer L Sherr6, Richard E Pratley7, Tamara S Hannon2, Viral N Shah8, Kellee M Miller9, Carla J Greenbaum3.   

Abstract

BACKGROUNDResidual C-peptide is detected in many people for years following the diagnosis of type 1 diabetes; however, the physiologic significance of low levels of detectable C-peptide is not known.METHODSWe studied 63 adults with type 1 diabetes classified by peak mixed-meal tolerance test (MMTT) C-peptide as negative (<0.007 pmol/mL; n = 15), low (0.017-0.200; n = 16), intermediate (>0.200-0.400; n = 15), or high (>0.400; n = 17). We compared the groups' glycemia from continuous glucose monitoring (CGM), β cell secretory responses from a glucose-potentiated arginine (GPA) test, insulin sensitivity from a hyperinsulinemic-euglycemic (EU) clamp, and glucose counterregulatory responses from a subsequent hypoglycemic (HYPO) clamp.RESULTSLow and intermediate MMTT C-peptide groups did not exhibit β cell secretory responses to hyperglycemia, whereas the high C-peptide group showed increases in both C-peptide and proinsulin (P ≤ 0.01). All groups with detectable MMTT C-peptide demonstrated acute C-peptide and proinsulin responses to arginine that were positively correlated with peak MMTT C-peptide (P < 0.0001 for both analytes). During the EU-HYPO clamp, C-peptide levels were proportionately suppressed in the low, intermediate, and high C-peptide compared with the negative group (P ≤ 0.0001), whereas glucagon increased from EU to HYPO only in the high C-peptide group compared with negative (P = 0.01). CGM demonstrated lower mean glucose and more time in range for the high C-peptide group.CONCLUSIONThese results indicate that in adults with type 1 diabetes, β cell responsiveness to hyperglycemia and α cell responsiveness to hypoglycemia are observed only at high levels of residual C-peptide that likely contribute to glycemic control.FUNDINGFunding for this work was provided by the Leona M. and Harry B. Helmsley Charitable Trust, the National Center for Advancing Translational Sciences, and the National Institute of Diabetes and Digestive and Kidney Diseases.

Entities:  

Keywords:  Beta cells; Diabetes; Endocrinology; Islet cells

Year:  2020        PMID: 31895699      PMCID: PMC7108933          DOI: 10.1172/JCI134057

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  63 in total

Review 1.  Abnormalities of the Exocrine Pancreas in Type 1 Diabetes.

Authors:  Martha Campbell-Thompson; Teresa Rodriguez-Calvo; Manuela Battaglia
Journal:  Curr Diab Rep       Date:  2015-10       Impact factor: 4.810

2.  The role of intramyocellular lipids during hypoglycemia in patients with intensively treated type 1 diabetes.

Authors:  Elisabeth Bernroider; Attila Brehm; Martin Krssak; Christian Anderwald; Zlatko Trajanoski; Gary Cline; Gerald I Shulman; Michael Roden
Journal:  J Clin Endocrinol Metab       Date:  2005-07-05       Impact factor: 5.958

3.  The significance of the portal insulin secretion in insulin dependent patients with residual beta-cell function: a safeguard against hormonal and metabolic derangement.

Authors:  S Madsbad; O K Faber; A Kurtz; T Krarup; L Regeur; B Tronier; H Orskov; C Binder; K G Alberti
Journal:  Clin Endocrinol (Oxf)       Date:  1982-06       Impact factor: 3.478

4.  Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide.

Authors:  Charles Thivolet; Lucien Marchand; Karim Chikh
Journal:  Diabetologia       Date:  2019-01-06       Impact factor: 10.122

5.  Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.

Authors: 
Journal:  Ann Intern Med       Date:  1998-04-01       Impact factor: 25.391

6.  Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.

Authors:  Michael W Steffes; Shalamar Sibley; Melissa Jackson; William Thomas
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

7.  Residual insulin secretion is not coupled to a maintained glucagon response to hypoglycaemia in long-term type 1 diabetes.

Authors:  S Sjöberg; B Ahrén; J Bolinder
Journal:  J Intern Med       Date:  2002-10       Impact factor: 8.989

8.  Magnitude and mechanisms of glucose counterregulation following islet transplantation in patients with type 1 diabetes suffering from severe hypoglycaemic episodes.

Authors:  Meidjie Ang; Christian Meyer; Mathias D Brendel; Reinhard G Bretzel; Thomas Linn
Journal:  Diabetologia       Date:  2013-12-05       Impact factor: 10.122

9.  The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells.

Authors:  Richard A Oram; Angus G Jones; Rachel E J Besser; Bridget A Knight; Beverley M Shields; Richard J Brown; Andrew T Hattersley; Timothy J McDonald
Journal:  Diabetologia       Date:  2014-01       Impact factor: 10.122

10.  Residual β-Cell function 3-6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents.

Authors:  Jesper S Sørensen; Jesper Johannesen; Flemming Pociot; Kurt Kristensen; Jane Thomsen; N Thomas Hertel; Per Kjaersgaard; Caroline Brorsson; Niels H Birkebaek
Journal:  Diabetes Care       Date:  2013-08-29       Impact factor: 19.112

View more
  25 in total

1.  Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia.

Authors:  Rose A Gubitosi-Klug; Barbara H Braffett; Susan Hitt; Valerie Arends; Diane Uschner; Kimberly Jones; Lisa Diminick; Amy B Karger; Andrew D Paterson; Delnaz Roshandel; Santica Marcovina; John M Lachin; Michael Steffes; Jerry P Palmer
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

Review 2.  Psychosocial Needs for Newly Diagnosed Youth with Type 1 Diabetes and Their Families.

Authors:  Susana R Patton; David Maahs; Priya Prahalad; Mark A Clements
Journal:  Curr Diab Rep       Date:  2022-06-21       Impact factor: 5.430

3.  Autocrine C-peptide protects INS1 β cells against palmitic acid-induced oxidative stress in peroxisomes by inducing catalase.

Authors:  Patrizia Luppi; Nicholas Drain; Ramsey To; Donna Stolz; Callen Wallace; Simon Watkins; Peter Drain
Journal:  Endocrinol Diabetes Metab       Date:  2020-05-30

4.  Relative Hypoxia and Early Diabetic Kidney Disease in Type 1 Diabetes.

Authors:  Carissa Vinovskis; Lu-Ping Li; Pottumarthi Prasad; Kalie Tommerdahl; Laura Pyle; Robert G Nelson; Meda E Pavkov; Daniel van Raalte; Marian Rewers; Marlon Pragnell; Farid H Mahmud; David Z Cherney; Richard J Johnson; Kristen J Nadeau; Petter Bjornstad
Journal:  Diabetes       Date:  2020-07-31       Impact factor: 9.461

5.  Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Wendy K Chung; Karel Erion; Jose C Florez; Andrew T Hattersley; Marie-France Hivert; Christine G Lee; Mark I McCarthy; John J Nolan; Jill M Norris; Ewan R Pearson; Louis Philipson; Allison T McElvaine; William T Cefalu; Stephen S Rich; Paul W Franks
Journal:  Diabetologia       Date:  2020-09       Impact factor: 10.122

6.  A little help from residual β cells has long-lasting clinical benefits.

Authors:  Anna Lam; Colin Dayan; Kevan C Herold
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

7.  Residual β-cell function after 10 years of autoimmune type 1 diabetes: prevalence, possible determinants, and implications for metabolism.

Authors:  Jin Cheng; Min Yin; Xiaohan Tang; Xiang Yan; Yuting Xie; Binbin He; Xia Li; Zhiguang Zhou
Journal:  Ann Transl Med       Date:  2021-04

8.  Islet sympathetic innervation and islet neuropathology in patients with type 1 diabetes.

Authors:  Martha Campbell-Thompson; Elizabeth A Butterworth; J Lucas Boatwright; Malavika A Nair; Lith H Nasif; Kamal Nasif; Andy Y Revell; Alberto Riva; Clayton E Mathews; Ivan C Gerling; Desmond A Schatz; Mark A Atkinson
Journal:  Sci Rep       Date:  2021-03-22       Impact factor: 4.379

Review 9.  Pancreatic islet reserve in type 1 diabetes.

Authors:  Anneliese J S Flatt; Carla J Greenbaum; James A M Shaw; Michael R Rickels
Journal:  Ann N Y Acad Sci       Date:  2021-02-06       Impact factor: 6.499

10.  C-peptide enhances glucagon secretion in response to hyperinsulinemia under euglycemic and hypoglycemic conditions.

Authors:  Mary Courtney Moore; Shana O Warner; Yufei Dai; Nicole Sheanon; Marta Smith; Ben Farmer; Rebecca L Cason; Alan D Cherrington; Jason J Winnick
Journal:  JCI Insight       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.